Reata, a wholly owned subsidiary of Biogen
Clinical trials sponsored by Reata, a wholly owned subsidiary of Biogen, explained in plain language.
Now part of
Biogen Inc.
BIIB
NASDAQ
A biopharmaceutical company (acquired by Biogen) developing treatments for rare diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.